TY - JOUR T1 - Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy JF - Anticancer Research JO - Anticancer Res SP - 2351 LP - 2357 DO - 10.21873/anticanres.16400 VL - 43 IS - 5 AU - SERIKA MATSUOKA AU - HIRONORI FUJII AU - HIROTOSHI IIHARA AU - KOICHI OHATA AU - CHIEMI HIROSE AU - DAICHI WATANABE AU - SHIORI SADAKA AU - SHIGERU KIYAMA AU - AKITAKA MAKIYAMA AU - TAKAO TAKAHASHI AU - RYO KOBAYASHI AU - NOBUHISA MATSUHASHI AU - AKIO SUZUKI Y1 - 2023/05/01 UR - http://ar.iiarjournals.org/content/43/5/2351.abstract N2 - Background/Aim: Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting. To identify risk factors for nausea and vomiting, we investigated the occurrence of nausea and vomiting in mCRC patients treated with TAS-102 and BEV. Patients and Methods: Study patients with mCRC received TAS-102 and BEV between March 2016 and December 2021. The status of nausea, vomiting, and antiemetic measures in each course were investigated, and factors involved in the occurrence of nausea and vomiting were analysed by logistic regression analysis. Results: Data from 57 patients were analysed. The incidence rates of nausea and vomiting during the overall period were 57.9% and 17.5%, respectively. Nausea and vomiting were frequent not only in the early courses but also after the sixth course. Multivariate logistic regression analysis showed that the experience of nausea and vomiting in previous treatment with other agents was significantly associated with nausea and vomiting with TAS-102 and BEV. Conclusion: The experience of nausea and vomiting in previous treatment was associated with increased risk for nausea and vomiting in mCRC patients treated with TAS-102 and BEV. ER -